The company behind the ‘Steroid Olympics,’ which has drawn attention for its controversial approach to performance-enhancing substances, is set to begin selling injectable peptides after the US health secretary indicated a potential shift in regulatory policy. The Enhanced Games, backed by high-profile investors including Peter Thiel and Donald Trump Jr., announced on Tuesday that it will start offering certain peptides for sale through an online health service. This move follows a public endorsement of peptides by Robert F. Kennedy Jr., who discussed their potential benefits on Joe Rogan’s podcast last month.

Impact on Consumer Health and Regulatory Framework

The Enhanced Games, a new sports event set to debut in Las Vegas in May, plans to include athletes competing in swimming, athletics, and weightlifting while using performance-enhancing drugs. The company is also seeking regulatory approval to list on the Nasdaq through a special-purpose acquisition company, with investors including 1789 Capital, Donald Trump Jr.’s firm, and Peter Thiel.

Maximilian Martin, the CEO of the Enhanced Games, stated that the company intends to invest heavily in the peptide market, citing its growing popularity worldwide. ‘Understanding how popular peptide usage has become globally, we intend to invest heavily in this space,’ Martin said. The company plans to initially offer five peptides for sale and may introduce eight additional ones once regulatory approval is secured.

However, the Food and Drug Administration (FDA) has historically imposed restrictions on peptide sales, citing safety concerns. The agency has warned that many peptides lack sufficient evidence regarding their effectiveness and safety. Despite these concerns, peptides have become widely accessible in the US, often imported from China due to production restrictions in the US.

Risks and Lack of Scientific Evidence

The FDA has raised concerns about the safety of several peptides that the Enhanced Games plans to sell, stating that they pose ‘potentially significant safety risks.’ Limited scientific evidence exists for several of these substances, and many have not undergone rigorous clinical trials. Peptides are often marketed as aids for hormone action and metabolism, but their effectiveness remains largely unproven.

Interest in peptides has grown in part due to the popularity of GLP-1 weight-loss drugs such as semaglutide and tirzepatide, which have gained traction among bodybuilders and members of the online ‘looksmaxxing’ subculture. These individuals often pursue radical health interventions to alter their appearance, contributing to the rising demand for performance-enhancing substances.

According to the Enhanced Games, more than 40 athletes have signed up to participate in the inaugural event, and the company claims that research conducted on these athletes will inform its personalized supplement offerings. However, critics argue that the event’s focus on performance-enhancing drugs undermines the integrity of competitive sports.

Legal and Market Implications

Edgar Asebey, a partner at the law firm Frier Levitt in Florida, noted that the Enhanced Games appears to be one of the first businesses to capitalize on the potential deregulation of peptides. ‘Everybody is trying to jump into this. We have a bunch of clients who all want to be first,’ he said. Other companies are also preparing to enter the market, suggesting a growing trend in the sale of these substances.

The FDA has not yet responded to requests for comment on Kennedy’s proposal to further deregulate the peptide market. The agency has historically maintained strict regulations on peptide sales, but the recent statements by Kennedy and the potential shift in policy may lead to a relaxation of these restrictions.

The Enhanced Games’ decision to sell peptides online raises questions about the oversight of these substances in the US. With limited scientific evidence and safety concerns, the company’s move highlights the need for greater regulatory scrutiny. The event’s approach to performance-enhancing drugs has drawn criticism from health experts and sports organizations, who argue that it promotes the use of unproven and potentially dangerous substances.

The company’s strategy to enter the consumer health sector through the sale of peptides may have far-reaching implications. If the FDA does not intervene, the market for these substances could expand significantly, leading to increased accessibility and potential risks for consumers. The Enhanced Games’ approach to performance-enhancing drugs could set a precedent for other companies seeking to capitalize on the growing demand for peptides.

As the company prepares to launch its peptide sales, the debate over the regulation of these substances is likely to intensify. The potential deregulation of peptides could have significant consequences for public health, sports integrity, and the broader pharmaceutical industry. The Enhanced Games’ role in this emerging market will be closely watched by regulators, health experts, and the public alike.